J. Le Treut

1.5k total citations
22 papers, 898 citations indexed

About

J. Le Treut is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J. Le Treut has authored 22 papers receiving a total of 898 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in J. Le Treut's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (7 papers). J. Le Treut is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (7 papers). J. Le Treut collaborates with scholars based in France, United States and Réunion. J. Le Treut's co-authors include A. Vergnenègre, H. Léna, G. Robinet, P. Thomas, P. Fournel, Éric Dansin, M. Pérol, Marie‐Cécile Bozonnat, F. Mornex and Pierre-Jean Souquet and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

J. Le Treut

17 papers receiving 880 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Le Treut France	10	701	496	139	112	104	22	898
Walburga Engel-Riedel Germany	15	556 0.8×	411 0.8×	72 0.5×	140 1.3×	125 1.2×	43	795
Samuel Marcrom United States	12	306 0.4×	221 0.4×	96 0.7×	53 0.5×	97 0.9×	32	544
Sherif Y. El Sharouni Netherlands	10	456 0.7×	498 1.0×	305 2.2×	29 0.3×	54 0.5×	26	728
Vinicius Ernani United States	14	423 0.6×	577 1.2×	205 1.5×	169 1.5×	27 0.3×	50	858
Jason C. Chandler United States	14	453 0.6×	742 1.5×	65 0.5×	101 0.9×	34 0.3×	41	1.1k
Felipe Couñago Spain	16	477 0.7×	325 0.7×	37 0.3×	113 1.0×	80 0.8×	110	812
A. Badzio Poland	15	169 0.2×	323 0.7×	169 1.2×	51 0.5×	70 0.7×	47	620
Nadia Pasinetti Italy	13	368 0.5×	270 0.5×	43 0.3×	160 1.4×	76 0.7×	38	809
Wieneke A. Buikhuisen Netherlands	16	623 0.9×	422 0.9×	255 1.8×	48 0.4×	45 0.4×	35	1.1k
Robert F. Marschke United States	16	275 0.4×	578 1.2×	257 1.8×	76 0.7×	27 0.3×	39	863

Countries citing papers authored by J. Le Treut

Since Specialization

Citations

This map shows the geographic impact of J. Le Treut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Le Treut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Le Treut more than expected).

Fields of papers citing papers by J. Le Treut

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Le Treut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Le Treut. The network helps show where J. Le Treut may publish in the future.

Co-authorship network of co-authors of J. Le Treut

This figure shows the co-authorship network connecting the top 25 collaborators of J. Le Treut. A scholar is included among the top collaborators of J. Le Treut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Le Treut. J. Le Treut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Auliac, J.B., P. Thomas, Olivier Bylicki, et al.. (2024). Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). Therapeutic Advances in Medical Oncology. 16. 3 indexed citations

Anota, Amélie, J.B. Auliac, L. Falchero, et al.. (2023). Concordance entre la stratégie thérapeutique proposée en RCP initiale et le traitement effectivement réalisé pour les CBPNC de stade III non opérables : résultats initiaux de l’étude OBSTINATE (GFPC 06-2019). Revue des Maladies Respiratoires Actualités. 15(1). 133–133.

Auliac, J.B., P. Thomas, Olivier Bylicki, et al.. (2022). 937P Incidence and outcomes of EGFR mutated non-small cell lung cancer treated with surgery: EXERPOS GFPC study. Annals of Oncology. 33. S976–S976.

Treut, J. Le, G. Le Garff, Olivier Bylicki, et al.. (2022). Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. Lung Cancer. 174. 45–49. 8 indexed citations

Pénaranda, Guillaume, C. Stavris, F. Rétornaz, et al.. (2021). Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. Therapeutics and Clinical Risk Management. Volume 17. 669–677. 9 indexed citations

Barlési, Fabrice, Laurent Greillier, F. Monville, et al.. (2020). LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study. Annals of Oncology. 31. S1183–S1183. 9 indexed citations

Trédaniel, Jean, L. Moreau, J. Le Treut, et al.. (2020). Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. Respiratory Medicine and Research. 80. 100795–100795. 9 indexed citations

Baize, Nathalie, I. Monnet, Laurent Greillier, et al.. (2019). OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial. Journal of Thoracic Oncology. 14(10). S246–S246. 5 indexed citations

Quoix, Élisabeth, Clarisse Audigier-Valette, A. Lavolé, et al.. (2018). Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial. Annals of Oncology. 29. viii744–viii745.

10.

Mazières, Julien, Fabrice Barlési, Xavier Quantin, et al.. (2018). Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial. Annals of Oncology. 29. viii538–viii539.

11.

Levra, Matteo Giaj, Silvia Novello, Fausto Barbieri, et al.. (2017). P1.06-005 An International Cohort of Patients with Small Cell Lung Cancer after a Non-Small Cell Lung Carcinoma Oncogene or Non-Oncogene Addicted. Journal of Thoracic Oncology. 12(1). S667–S667.

12.

Barlési, Fabrice, C. Chouaïd, Jacky Créquit, et al.. (2015). A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. Interactive Cardiovascular and Thoracic Surgery. 20(6). 783–790. 9 indexed citations

13.

Corre, R., C. Chouaïd, Laurent Greillier, et al.. (2014). Quality of Life Analysis of Esogia-Gfpc-Gecp Trial- a Phase Iii, Randomized, Multicenter Study Comparing in Elderly Patients (≥70 Years) with Stage Iv Nsclc a Treatment Allocation Based on Ps and Age with an Experimental Strategy According to a Comprehensive Geriatric Assessment (Cga). Annals of Oncology. 25. iv436–iv436. 2 indexed citations

14.

Chouaïd, C., C. Dujon, Pascal Dô, et al.. (2014). Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 86(2). 170–173. 132 indexed citations

15.

Treut, J. Le, H. Léna, P.-J. Souquet, et al.. (2013). Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Annals of Oncology. 24(6). 1548–1552. 111 indexed citations

16.

Locher, Chrystèle, D. Debieuvre, D. Coëtmeur, et al.. (2013). Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies. Lung Cancer. 81(1). 32–38. 74 indexed citations

17.

Grivaux, M, P. Bombaron, T. Collon, et al.. (2010). Étude KBP-2010-CPHG : recueil des nouveaux cas de cancer bronchopulmonaire primitif diagnostiqués dans les services de pneumologie des centres hospitaliers généraux du 1er janvier au 31 décembre 2010. Revue de Pneumologie Clinique. 66(6). 375–382. 18 indexed citations

18.

Maurice, Roch L., et al.. (2005). Anévrisme d'un pontage veineux aortocoronarien : à propos d'un cas de découverte fortuite. Annales de Cardiologie et d Angéiologie. 55(4). 230–232. 1 indexed citations

19.

Fournel, P., G. Robinet, P. Thomas, et al.. (2005). Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique–Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. Journal of Clinical Oncology. 23(25). 5910–5917. 411 indexed citations

20.

Robinet, G., H. Léna, A. Vergnenègre, et al.. (2001). Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): A French randomized phase III trial of GLOT-GFPC (NPC 95-01 study). European Journal of Cancer. 37. S28–S28. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact